Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for Macrogenics (MGNX) over the last 14 years, with Q3 2025 value amounting to $55.8 million.

  • Macrogenics' Non-Current Deffered Revenue rose 60.72% to $55.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.8 million, marking a year-over-year increase of 60.72%. This contributed to the annual value of $55.5 million for FY2024, which is 631.3% down from last year.
  • As of Q3 2025, Macrogenics' Non-Current Deffered Revenue stood at $55.8 million, which was up 60.72% from $55.7 million recorded in Q2 2025.
  • Macrogenics' Non-Current Deffered Revenue's 5-year high stood at $64.3 million during Q3 2023, with a 5-year trough of $5.1 million in Q3 2022.
  • Over the past 5 years, Macrogenics' median Non-Current Deffered Revenue value was $55.6 million (recorded in 2024), while the average stood at $41.0 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first crashed by 5426.68% in 2022, then soared by 116396.54% in 2023.
  • Quarter analysis of 5 years shows Macrogenics' Non-Current Deffered Revenue stood at $9.6 million in 2021, then skyrocketed by 521.2% to $59.5 million in 2022, then dropped by 0.4% to $59.2 million in 2023, then decreased by 6.31% to $55.5 million in 2024, then increased by 0.61% to $55.8 million in 2025.
  • Its Non-Current Deffered Revenue stands at $55.8 million for Q3 2025, versus $55.7 million for Q2 2025 and $55.9 million for Q1 2025.